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http://dx.doi.org/10.1016/j.ccell.2016.08.016SUMMARYNeuroblastoma is a pediatric embryonal malignancy characterized by impaired neuronal differentiation.
A better understanding of neuroblastoma differentiation is essential for developing new therapeutic
approaches. GDE2 (encoded by GDPD5) is a six-transmembrane-domain glycerophosphodiesterase
that promotes embryonic neurogenesis. We find that high GDPD5 expression is strongly associated
with favorable outcome in neuroblastoma. GDE2 induces differentiation of neuroblastoma cells, sup-
presses cell motility, and opposes RhoA-driven neurite retraction. GDE2 alters the Rac-RhoA activity
balance and the expression of multiple differentiation-associated genes. Mechanistically, GDE2 acts
by cleaving (in cis) and releasing glycosylphosphatidylinositol-anchored glypican-6, a putative co-re-
ceptor. A single point mutation in the ectodomain abolishes GDE2 function. Our results reveal GDE2
as a cell-autonomous inducer of neuroblastoma differentiation with prognostic significance and poten-
tial therapeutic value.INTRODUCTION
Neuroblastoma is a childhood cancer of the developing sympa-
thetic nervous system, and themost common cancer in infancy.
It develops from immature neuroblasts in the embryonic neural
crest and is characterized by impaired neuronal differentiation
(Jiang et al., 2011; Louis and Shohet, 2015; Maris, 2010). It
commonly originates in the adrenal gland, but can also develop
in nerve tissues elsewhere in the body. Neuroblastoma is aSignificance
Neuroblastoma is a childhood cancer characterized by impair
standing of differentiation regulatory pathways is crucial to the
GDE2 is a transmembrane glycerophosphodiesterase with a ca
esis. We show that GDE2 induces neuroblastoma cell differen
patient cohorts. GDE2 activates Rac, inhibits RhoA-driven neu
ated genes. Mechanistically, GDE2 acts by releasing GPI-anch
neuronal differentiation in a cell-autonomousmanner. Our work
differentiation by a GPI-specific phosphodiesterase, thereby s
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This is an open access article under the CC BY-NC-ND license (http://highly heterogeneous disease. In some cases, the tumor un-
dergoes spontaneous regression through mechanisms that
remain poorly understood (Brodeur and Bagatell, 2014). In
many cases, however, neuroblastoma progresses into a high-
risk metastatic disease with very poor prognosis. Remarkably,
high-risk neuroblastoma is characterized by relatively few re-
current somatic mutations (Molenaar et al., 2012; Pugh et al.,
2013). The paucity of oncogenic mutations, along with an
incomplete understanding of neuroblastoma differentiationed differentiation of immature neuroblasts. A better under-
development of new therapies for this often fatal malignancy.
talytic ectodomain known to promote embryonic neurogen-
tiation and is a favorable prognostic marker in independent
rite retraction, and regulates multiple differentiation-associ-
ored glypican-6, a putative co-receptor or ligand, to signal
reveals a previously unknownmechanismof neuroblastoma
uggesting new therapeutic possibilities.
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. GDE2: Its Family Members and
Prognostic Significance in Neuroblastoma
(A) GDE2 (or GDPD5) and its close relatives GDE3
(GDPD2) and GDE6 (GDPD4) contain six trans-
membrane domains and a large catalytic ectodo-
main, as illustrated.
(B) Schematic representation of GDE2, with five
potential N-glycosylation sites indicated.
(C) Kaplan-Meier analysis of overall survival in
three independent neuroblastoma patient cohorts,
as indicated: Oberthuer (n = 251; ArrayExpress:
E-TABM-38), Neuroblastoma RPM/SEQC (n =
498; GEO: GSE62564), and AMC/Versteeg (n =
122; GEO: GSE16476 88/122). The graphs depict
the p values corrected for the multiple testing
(Bonferroni correction) of cutoff levels for GDPD5.
Family members GDPD2 and GDPD4 were not
detectably expressed in the tumor samples
analyzed.and regression, hampers the development of new targeted
therapies.
In general, overall survival of neuroblastoma patients is
largely dependent on the degree of neuronal differentiation
and, furthermore, inversely correlated with a motile phenotype
(Louis and Shohet, 2015; van Nes et al., 2013). Consistent
with this, some high-risk neuroblastomas are associated with
mutations in Rac-Rho pathway genes that normally regulate
F-actin-based neurite outgrowth and remodeling, as well as tu-
mor cell motility, invasion, and metastasis (Molenaar et al.,
2012). Unfortunately, treatment options are very limited for
high-risk neuroblastoma. One strategy involves differentiation
therapy using cis-retinoic acid, but this has led to disappointing
results (Ganeshan and Schor, 2011; Holzel et al., 2010; Matthay
et al., 2009). Thus, there remains an urgent need to identify
new therapeutic targets and develop differentiation-inducing
protocols (Brodeur et al., 2014). A better understanding of neu-
roblastoma differentiation at the molecular level is therefore
imperative.
In this study we focus on GDE2 (or GDPD5), a trans-
membrane ecto-phosphodiesterase that promotes embry-
onic neurogenesis (Rao and Sockanathan, 2005). GDE2/
GDPD5, along with GDE3/GDPD2 and GDE6/GDPD4, belongs
to a subfamily of glycerophosphodiester phosphodiesterases
(GDEs or GDPDs) characterized by six transmembrane do-
mains and a large catalytic ectodomain (Corda et al., 2014;
Yanaka, 2007) (Figures 1A and 1B). GDE2 promotes the differ-
entiation of postmitotic motor neurons in vivo by inhibiting
Notch signaling in adjacent neural progenitors (Sabharwal
et al., 2011). GDE3 has been implicated in osteoblast differen-
tiation (Corda et al., 2009; Yanaka et al., 2003), while the
function of GDE6 is unknown. Mechanistically, GDE2 acts
by cleaving the gycosylphosphatidylinositol (GPI) anchor ofCancRECK, a Notch ligand regulator, leading
to RECK release from the cell surface
and subsequent induction of differentia-
tion in contacting neuronal cells (Park
et al., 2013). Thus, GDE2 promotes
neurogenesis in a non-cell-autonomousmanner, requiring cell-cell contact, at least in the developing
spinal cord.
In view of these findings, we set out to examine a possible role
of GDE2 in regulating neuroblastoma differentiation.
RESULTS
GDPD5 Expression Levels Strongly Correlate with
Clinical Outcome in Neuroblastoma
We examined how GDPD5 expression relates to overall survival
in neuroblastoma, usingmRNA expression data of primary tumor
samples from three independent patient cohorts (AMC, Oberth-
uer, and RPM datasets; n = 871 patients).GDPD5maps to chro-
mosome 11q13, a region often showing loss of heterozygosity in
neuroblastoma (Jiang et al., 2011), Kaplan-Meier analysis re-
vealed that high GDPD5 expression is strongly associated with
favorable clinical outcome, while low GDPD5 expression corre-
lates with poor outcome in all three patient cohorts (Figure 1C).
This marks GDPD5 as a potential tumor suppressor, but no mu-
tations or deletions were detected in tumor samples analyzed by
whole-genome sequencing (Molenaar et al., 2012). Furthermore,
GDPD5 expression in patients with an 11q deletion was similar to
those with a normal chromosome 11, while there was no signif-
icant association withMYCN amplification (p = 0.08) or ALKmu-
tation status (p = 0.66, Fisher’s exact test; data not shown).
GDE2 promotes neurogenesis through loss of functional
RECK (Park et al., 2013); however, we found no significant cor-
relation between RECK expression and patient survival (data
not shown). Of note, GDE2 familymembersGDE3 andGDE6 (en-
coded by GDPD2 and GDPD4, respectively; Figure 1A) were not
detectably expressed at the mRNA level in the tumors analyzed,
and therefore appear not to have clinical significance in neuro-
blastoma. These results define high GDPD5 expression as aer Cell 30, 548–562, October 10, 2016 549
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favorable prognostic marker in neuroblastoma. We went on to
examine how GDE2 affects neuroblastoma cell behavior and to
explore its signaling functions and pertinent catalytic activity.
GDE2 Promotes Differentiation of Neuroblastoma Cells
in an Autonomous Manner
We used established models of neuroblastoma differentiation,
including SH-SY5Y, IMR-32, Neuro-2A and N1E-115 cells; in
the latter cells, Rho/Rac signaling and neurite remodeling path-
ways have been extensively studied. Overexpression of GDE2
in N1E-115 or Neuro-2A cells resulted in prominent cell
spreading and neurite outgrowth (Figures 2A–2C and S1A). Simi-
larly, expression of doxycycline-inducible GDE2 in either SH-
SY5Y or IMR-32 cells led to GDE2 overexpression concomitant
with increased neurite outgrowth after doxycycline addition (Fig-
ures 2D and 2E). GDE2-induced neurite outgrowth was accom-
panied by upregulation of various established neural differentia-
tion genes, including NEUROD1, SNAP25, ENO2, TUBB3, and
MAP2 (Figure 2F).
During embryonic development, GDE2 promotes neurogene-
sis in non-cell-autonomous manner involving contact-depen-
dent Notch signaling (Sabharwal et al., 2011). In neuroblastoma
cells, however, GDE2-induced cell spreading and neurite
formation was observed in both isolated and contacting cells
(Figure S1B). Furthermore, conditioned medium from GDE2-
overexpressing cells did not affect the morphology of parental
cells (results not shown), arguing against the involvement of a
diffusible factor produced by GDE2. It thus appears that GDE2
promotes neuroblastoma differentiation in a cell-autonomous
manner, not requiring cell-cell contact.
Various human neuroblastoma cells, including SH-SY5Y, are
responsive to retinoic acid (RA), a known inducer of neuronal dif-
ferentiation that is used as a therapeutic in the clinic (Brodeur,
2003; Brodeur et al., 2014; Matthay et al., 2009). RA upregulates
GDE2 expression in the ventricular zone (Rao and Sockanathan,
2005) and in Neuro-2A cells (Yanaka et al., 2007), but it did not in
SH-SY5Y cells (Figure S1C). Upon forced overexpression in SH-
SY5Y cells, GDE2 enhanced the neurite-inducing effect of RA
(2 mM) (Figure S1D), strongly suggesting that GDE2 and RA act
cooperatively to induce differentiation.Figure 2. GDE2 Induces Neuroblastoma Cell Differentiation and Suppr
(A and B) Images of N1E-115 cells expressing GDE2-mCh or GDE2-GFP. Note fla
arrowheads) when compared with non-transfected cells. Scale bar, 10 mm. In (B
empty vector were used as control. GDE2-GFP is shown in green and F-actin in
(C) Quantitative analysis of distinct morphologies of GDE2-overexpressing versus
error bars denote mean ± SEM). (Left) Percentage of cells with a round or flattene
(Right) Neurite length. ****p < 0.0001, Fisher’s (left, middle) and unpaired t tests (
(D) SH-SY5Y and IMR-32 cells containing doxycyclin (Dox)-inducible GDE2 show
anti-GDE2 antibody) show Dox-induced GDE2 expression over a 3- to 72-hr tim
(E) Quantification of Dox-induced neurite outgrowth (n = 250 cells; mean ± SEM
(F) Dox-induced GDE2 overexpression promotes induction of neural differentiatio
and GAP43, as determined by qPCR in SH-SY5Y cells. Error bars denote SEM o
(G) Dox-induced GDE2 overexpression promotes cell-matrix adhesion. At 1 hr a
crystal violet for quantification. Error bars denote SD of two independent experim
(H) Random cell motility of individual SH-SY5Y and IMR-32 cells expressing ind
were generated from time-lapsemovies (12 hr, 10-min intervals). Graphs showme
IMR-32 cells.
In (E) to (H), *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001, unpaired t test.
See also Figure S1.GDE2-overexpresssing SH-SY5Y and IMR-32 cells adhered
markedly more strongly to extracellular matrix molecules (lami-
nin, fibronectin, collagen) than did the parental cells (Figure 2G).
Cell-matrix adhesion is a major determinant of cell motility, and a
motile phenotype is associated with increased incidence of me-
tastases and poor prognosis in neuroblastoma (van Nes et al.,
2013). By monitoring the random motility of SH-SY5Y and
IMR-32 cells, we established that GDE2 overexpression renders
the cells less motile than the wild-type cells (Figure 2H).
When expressed at relatively low levels, GDE2 was detected
both at the plasma membrane and in intracellular compartments
as revealed by confocal and super-resolution microscopy (Fig-
ures S1E and S1F). PlasmamembraneGDE2 localized to distinct
microdomains, possibly representing lipid rafts, and was partic-
ularly enriched at the tips of neurite-like extensions (Figure S1F).
Intracellularly, a relatively large subset of GDE2-containing ves-
icles was positive for established markers of recycling endo-
somes, notably Rab11 and the transferrin receptor (Grant and
Donaldson, 2009; Welz et al., 2014) (Figures S1G and S1H).
This suggests that internalized GDE2 follows a Rab11-driven re-
cycling route as a way of regulation. We further note that, once
internalized, GDE2 has its catalytic ectodomain exposed to the
vesicle lumen and hence cannot act on cytosolic substrates.
GDE2 Opposes RhoA-Mediated Neurite Retraction and
Activates Rac
Rho guanosine triphosphatases, particularly RhoA, Rac, and
Cdc42, are key regulators of F-actin-driven processes, including
neuronal differentiation, cell adhesion, motility, and invasion (Go-
vek et al., 2005; Hall, 2012; Hall and Lalli, 2010; Ridley, 2015;
Spuul et al., 2014). One hallmark of developing neurites is their
susceptibility to acute retraction by RhoA-activating agonists
such as lysophosphatidic acid (LPA), a lipid mediator acting on
specific G-protein-coupled receptors. As such, LPA antagonizes
the phenotypic differentiation of neuroblastoma and neural/stem
progenitor cells (Frisca et al., 2013; Hirose et al., 1998; Jalink
et al., 1994; Kranenburg et al., 1999; Moolenaar, 1995). Strik-
ingly, GDE2-overexpressing N1E-115 cells were unable to
retract their developing neurites and round up in response to
LPA, whereas the parental cells responded vigorously (Figuresesses Cell Motility
ttenedmorphology and neurite outgrowth in GDE2-ovexpressing cells (A, black
), cells were stained with phalloidin to visualize F-actin. Cells transfected with
red. Scale bar, 10 mm.
empty vector-expressing cells (three independent experiments; n > 300 cells;
d morphology (assayed in the presence of serum). (Middle) Neurite induction.
right).
longer neurites after addition of 1 mM Dox (black arrows). Immunoblots (using
e period. Scale bars, 100 mm.
). ****p < 0.0001, unpaired t tests.
n marker genes NEUROD1, SNAP25, ENO2, TUBB3, andMAP2, but not NPY
f triplicate measurements.
fter plating, adherent SH-SY5Y and IMR-32 cells were fixed and stained with
ents. *p < 0.05, **p < 0.01, t tests.
ucible GDE2-mCh (red) or empty vector (black), plated on fibronectin. Tracks
anmigration distances of control versus GDE2-mCh-expressing SH0SY5Y and
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Figure 3. GDE2 Opposes RhoA-Driven Neurite Retraction by LPA and Activates Rac
(A) Serum-starved N1E-115 cells expressing GDE2-mCh were stimulated with 1 mM LPA for the indicated times. GDE2-mCh-expressing cells are indicated by
black arrowheads and non-transfected cells by white arrowheads. Scale bars, 10 mm.
(legend continued on next page)
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3A, 3B, and S2; Movies S1 and S2). The apparent loss of LPA/
GPCR responsiveness upon GDE2 overexpression is reminis-
cent of an activated Tiam1-Rac phenotype, wherein Rac hyper-
activation is sufficient to inhibit LPA/RhoA-induced cytoskeletal
contraction (Leeuwen et al., 1997; Sander et al., 1999). GDE2-
overexpressing N1E-115 or SH-SY5Y cells indeed showed a
marked increase in basal Rac activity, which was insensitive to
LPA stimulation (Figure 3C). Furthermore, we confirmed that
expression of hyperactive Rac(L61A) induced prominent neuro-
blastoma cell spreading and conferred complete resistance to
cytoskeletal contraction by LPA (results not shown).
Active Rac is known to oppose RhoA at multiple levels (Govek
et al., 2005; Guilluy et al., 2011; Leeuwen et al., 1997; Nakamura,
2013; Sander et al., 1999).Wemonitored LPA-inducedRhoA acti-
vation in real timeusing anRhoA-specific fluorescence resonance
energy transfer (FRET)-based biosensor, as described by Ked-
ziora et al. (2016). In parental N1E-115 cells, LPA evoked an im-
mediate increase in RhoA activity that gradually leveled off to a
sustained elevated level (Figure 3D). Upon GDE2 overexpression,
however, the magnitude of LPA-induced RhoA activation was
reduced by about 3-fold (Figure 3D). Decreased RhoA activation
was also observed in SH-SY5Y cells (Figure 3D). Furthermore,
overexpressed GDE2 opposed constitutively active RhoA(V14A)
in promoting cell contraction, again consistent with an activated
Rac phenotype (Figure 3E). From these results, along with previ-
ous findings on Rac-RhoA antagonism, we conclude that high
GDE2 expression prevents neurite retraction by activating Rac
and opposes RhoA action both at the level of RhoA-guanosine
triphosphate (GTP) accumulation and more downstream.
GDE2 Depletion Reverses the GDE2 Overexpression
Phenotype and Uncovers GDE2-Regulated Gene
Expression
Since low GDPD5 expression correlates with poor clinical
outcome, we examined how GDE2 depletion affects neuroblas-
toma phenotype through lentiviral small hairpin RNA (shRNA)
transduction. To this end, we used Shep2 cells, since these cells
show relatively highGDPD5 expression among 24 human neuro-
blastoma cell lines analyzed (Figures 4A and S3). Using two (out
of five) independent shRNAs, we achieved efficient GDE2 knock-
down (Figure 4B). When compared with shControl cells, GDE2-
depleted Shep2 cells were less well spread and smaller in size,
and showed a reduction in basal Rac1 activity, which was now
sensitive to LPA stimulation (Figure 4C). This was accompanied
by marked cytoskeletal reorganization, fewer focal adhesions,
and reduced cell-matrix adhesion (Figures 4D–4G). Moreover,(B) Quantification of LPA-induced cell rounding over time in control and GDE2-ove
t test.
(C) Rac activity was measured in cells expressing empty vector (pcDNA3) or G
comparedwith total Rac levels in lysates of the same transfectants. (Left) Effect of
versus total Rac levels in the presence or absence of LPA (mean ± SEMof three ind
Rac activity in SH-SY5Y cells as a function of GDE2 expression and LPA stimula
(D) (Left) Activation of RhoA in N1E-115 cells expressing either GDE2-mCherry
biosensor. An increase in YFP/CFP ratio indicates increased RhoA activity (see
mean ± SEM). **p < 0.01, Wilcoxon test. (Right) Western blot of RhoA-GTP level
(E) Confocal images of N1E-115 cells transfected with Myc-RhoA(V14A) or co-
RhoA(V14A) in green. Bar graph shows quantitation of morphology of RhoA(V1
mean ± SEM). *p < 0.05, unpaired t test. Scale bars, 10 mm.
See also Figure S2; Movies S1 and S2.GDE2 knockdown cells migrated faster and over longer dis-
tances than did shControl cells (Figure 4H). Shep2 cells were
poorly responsive to LPA; upon GDE2 depletion, however, they
showed more pronounced cytoskeletal contraction induced by
LPA (results not shown). The knockdown phenotypes could be
rescued by expression of RNAi-resistant GDE2, indicating that
the observed effects are specific for GDE2 depletion (Figures
4D–4H). Thus, GDE2 knockdown evokes phenotypic changes
opposite to those induced by GDE2 overexpression.
Having shown that GDE2 activates Rac1 and opposes RhoA,
we next examined howGDE2may dictate neuroblastoma pheno-
type at the gene expression level. We analyzed differential gene
expression inGDE2 knockdown versus shControl Shep2 cells us-
ing genome-wide RNA sequencing (RNA-seq). In duplicate ex-
periments, RNA-seq-based analysis revealed 121 differentially
expressed genes (log2 fold change >1.5; p < 0.001) (Figure 4I
and Table S1). The list of differentially expressed geneswasmark-
edly enriched (18%; 22/121) in those involved in neuronal differen-
tiation, such as RELN, NTM, ROBO4, RNF112, PLPPR4, KIR-
REL3, and various genes (15%; 18/121) that regulate cell
adhesion (LAMA4, COL6A3, COL13A1, FN1, ITGA10, ITGA11)
and extracellular matrix organization (Table S1 and Figure 4I). It
is also noteworthy that some20% (26/121) of theGDE2-regulated
genes encodes proteins involved in transmembrane receptor ac-
tivity, including signaling by receptor tyrosine kinases (EPHB6,
PDGFRA, TIE1,ERBB4), GPCRs,Wnt, Hedgehog, and transform-
ing growth factor b (TGF-b) receptors, several of which play a role
in neurodevelopment (Table S1). These data suggest a scenario in
which a unique set of differentiation regulatory genes, along with
Rac hyperactivation, dictates the observed GDE2 phenotypes,
and may help explain the marked correlation between GDPD5
expression and patient survival.
GDE2 Biochemical Activity: Release of GPI-Anchored
Glypican-6
What is the relevant catalytic activity of GDE2 and how does
it relate to the observed differentiated phenotype? Immunopre-
cipitated GDE2 hydrolyzes glycerophosphocholine into glycerol
3-phosphate (Gallazzini et al., 2008), but this reaction has no
signaling relevance. We examined GDE2 enzymatic activity using
cell-based assays and mutational analysis. Prompted by the dis-
covery that chicken GDE2 induces the release of GPI-anchored
RECK from HEK293 cells (Park et al., 2013), we measured
GDE2 activity toward selected GPI-anchored proteins, including
RECKandglypicans (GPCs). GPCsare a family of six heparan sul-
fate proteoglycans that function as co-receptors or ligands torexpressing cells (n = 200 cells; mean ± SEM). *p < 0.05; ***p < 0.001, unpaired
DE2-GFP. Active GTP-bound Rac was assessed by pull-down assays and
LPA stimulation on Rac-GTP levels. (Middle) Densitometry analysis of Rac-GTP
ependent experiments). *p < 0.05, unpaired t test. (Right)Western blot showing
tion.
(red trace) or mCherry-CAAX (black trace) was monitored by an FRET-based
Experimental Procedures). (Middle) Maximum RhoA activation by LPA (n = 9,
s in doxycyclin (Dox)-induced SH-SY5Y cells.
transfected with GDE2-mCh and stained for Myc. GDE2 is shown in red and
4A)-expressing versus RhoA(V14A)/GDE2 co-expressing cells (n = 300 cells,
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regulate diverse signaling pathways, either positively or nega-
tively, particularly those involved in morphogenesis and neurode-
velopment (Allen et al., 2012; Filmus et al., 2008; Veugelers et al.,
1999). We co-expressed GDE2 and its candidate substrates,
confirmed their proper expression at the plasma membrane (Fig-
ures S4A–S4C and data not shown), and assayed cell lysates and
the medium for substrate release by immunoblotting, essentially
as described by Park et al. (2013).
We confirmed that chicken GDE2 promotes the release of
RECK, as did exogenous PI-PLC (Figure 5A). Unexpectedly,
however, our efforts to detect RECK release by human GDE2
were unsuccessful (Figure 5A), suggesting that GDE2 substrate
preferences may vary among vertebrates. We then examined
the GPI-anchored GPCs as potential substrates. Human GDE2
induced the release of GPC3 and GPC6, but not that of GPCs
1, 2, 4, and 5 (Figures S4D and 5C). This indicates that GDE2
shows selectivity toward GPC family members, likely due to
structural differences in the respective heparan sulfate chains
and/or the GPI-anchor core.
GPC6 is widely expressed among neuroblastoma cell lines
(FigureS4E), whileGPC3expression ismore variable (FigureS4F).
SH-SY5Y and N1E-115 cells express GPC6 but not GPC3 (Fig-
ures S4E–S4Gand 7A). We therefore focused our subsequent ex-
periments onGPC6. As onewould predict, when co-expressed in
N1E-115 cells, GDE2 and GPC6 co-localized in part to the same
membrane microdomains (Figures S4B and S4C).
Mutating His233 Abolishes GDE2 Function
Uncertainty still exists as to the active site of GDE2. Residue
His275 was reported to be critical for GDE2-induced neurogen-
esis (Rao and Sockanathan, 2005). Another potential catalytic
residue is His233, located in a conserved GHRG motif (Yanaka,
2007) (Figure 5B). As shown in Figure 5C, mutants GDE2(H233A)
and GDE2(H233A/275A) failed to induce the release of GPC6,
whereas the H275A mutation reduced GDE2 activity only
partially. This result defines His233 as a key catalytic residue.
Previous in vivo studies suggested that GDE2 activity is
enhanced after reduction of a putative disulfide bond (Cys25-
Cys576) linking the N- and C-terminal tails (Yan et al., 2009)Figure 4. GDE2 Depletion Reverses the GDE2 Overexpression Phenoty
(A) Immunoblot of GDE2 expression in the indicated cell lines, using anti-GDE2 a
(B) (Left)GDPD5 expression (relative toGAPDH) in control and GDE2-depleted Sh
was obtained with hairpins #4 and #5. Error bars denote mean ± SEM. **p < 0.0
expression using five different hairpins, as indicated. Actin was used as loading
(C) Rac-GTP levels in control and GDE2-depleted Shep2 cells (using hairpin #4).
(D) Cell morphology and cytoskeletal organization (phalloidin and vinculin staining)
rescues the phenotype, as indicated. Black scale bars, 100 mm; white scale bars
(E) Immunoblot showing GDE2 expression in control, GDE2-depleted, and ‘‘GDE
(F) Quantification of focal adhesion area in control, GDE2-depleted, and GDE
****p < 0.0001, one-way ANOVA.
(G) Cell-matrix adhesion of control, GDE2-depleted, and rescued Shep2 cells. Ce
were fixed and stained with crystal violet for quantification. Graph shows mean ±
(H) Analysis of random cell motility. (Left) Traces from individual cells are shown
generated from time-lapse movies. Images were captured every 10 min for 12 hr.
**p < 0.01, ****p < 0.0001, unpaired t test.
(I) (Left) Heatmap showing differentially expressed genes upon GDE2 silencing
change >1.5; p < 0.001). Experiments were performed in duplicate, as indicated.
S1. (Right) Bar graph shows the GO terms that are significantly enriched among t
pathways mediated by G-protein-coupled receptors, receptor protein tyrosine k
See also Table S1.(Figure 5B), but the catalytic activity of relevant Cys mutants was
not examined. In ourGPC releaseassay, the supposedly hyperac-
tive mutant GDE2(C25S), lacking the putative disulfide bond,
showed the same catalytic activity aswild-type GDE2 (Figure 5D).
This argues against a critical role for Cys25-Cys576 disulfide
bonding/reduction in regulating GDE2 activity under the present
assay conditions. Finally, to establish whether GDE2 acts in cis
(same cell) or/and in trans (adjacent cell), we mixed GDE2-ex-
pressing cells (lackingGPC6)withGPC6-expressing cells (lacking
GDE2) andmeasuredGPC6 release.GDE2-expressing cells were
incapable of promoting GPC6 release from adjacent cells (Fig-
ure 5E). It thus appears that GDE2 acts in cis, consistent with
GDE2 promoting differentiation in a cell-autonomous manner,
not requiring intercellular contacts.
When expressed in N1E-115 cells, catalytically dead
GDE2(H233A) failed to promote cell spreading and neurite for-
mation. GDE2(H275A) induced an intermediate phenotype, while
the C25S mutation had no effect (Figures 6A–6C), consistent
with the above biochemical data. In addition, GDE2(H233A)-
overexpressing cells showed a normal contractile response to
LPA (results not shown). Thus, GDE2 catalytic activity is neces-
sary and sufficient to induce neuroblastoma cell differentiation
and inhibit agonist-induced neurite retraction.
GPC6 Underexpression Phenocopies GDE2
Overexpression and Correlates with Favorable Disease
Outcome
We next asked to what extent GPC6 release may account for the
biological activity of GDE2. Using SH-SY5Y cells, which express
GPC6 as the only relevant GPC (Figure 7A), we established that
doxycyclin-induced GDE2 expression promotes the release of
endogenous GPC6 from the cell surface as measured by flow
cytometry (Figure 7B).
GPC6 release from the cell surface predicts loss of GPC6
function. We stably knocked down GPC6 in SH-SY5Y cells by
lentiviral transduction of different shRNAs (Figure 7C). GPC6
knockdown cells showed enhanced basal Rac1 activity, which
was sensitive to LPA stimulation (Figure 7D), and increased neu-
rite outgrowth (Figure 7E). To validate the knockdown result, wepe and Uncovers GDE2-Regulated Gene Expression
ntibody. See Figure S3 for GDPD5 mRNA expression analysis.
ep2 cells stably expressing shRNAs against GDE2. Maximal GDE2 knockdown
1, ***p < 0.001, unpaired t test. (Right) Immunoblot analysis of GDE2 protein
control.
in control andGDE2-depleted Shep2 cells. Expression of RNAi-resistant GDE2
, 10 mm.
2-rescued’’ Shep2 cells (transfected with RNAi-resistant GDE2).
2-rescued Shep2 cells using ImageJ software (n = 20 cells; mean ± SEM).
lls were plated on fibronectin or collagen. At 30 min after plating, adherent cells
SEM of two independent experiments. **p < 0.01, ***p < 0.001, unpaired t test.
(control, GDE2-depleted, and GDE2-rescued cells, as indicated). Tracks were
(Right) Quantification of mean migration distances (nR 60 cells, mean ± SEM).
in Shep2 cells as determined by whole-genome RNA-seq (cutoff: log2 fold
For the complete list of genes with gene ontology (GO) annotations, see Table
he differentially expressed genes. Transmembrane receptor signaling includes
inases, TGF-b, Wnt, and Hedgehog.
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Figure 5. GDE2 Selectively Cleaves Glypican-
6: Residue His233 Is Essential for Activity
(A) HEK293 cells were co-transfected with RECK
and either human GDE2-HA (hGDE2) or chicken
GDE2-FLAG (cGDE2). Expression levels were as-
sessed by immunoblotting in cell lysates and
conditioned medium. PI-PLC was used as positive
control in all experiments.
(B) Schematic of mutations made in GDE2. See text
for details.
(C) HEK293 cells were co-transfected with GPC6-
HA and GDE2-mCh or the indicated mutants
(GDE2(H27A), GDE2(H233A), GDE2(H233A/H275A)).
ThebargraphshowsquantificationofGPC6 released
into themedium,asquantifiedusing ImageJsoftware
and expressed as GPC6 release relative to that in
control cells. Error bars denote mean ± SEM of three
independent experiments.
(D)HEK293 cells transfectedwithGPC6-HA together
with either GDE2-mCh or mutant GDE2(C25S)-
mCh. Quantification of GPC6 release (bar graph) as
in (C).
(E) (Left) Scheme of the assay in HEK293 cells.
GPC6-HA and GDE2-mCh co-transfected HEK293
cells or transfected with either GPC6-HA or GDE2-
mCh were mixed and plated in polyethyleneimine-
coated plates. (Right) After 24 hr incubation in
serum-free medium, GPC6 in the medium and cell
lysates was analyzed by western blotting.
See also Figure S4.knocked out GPC6 using CRISPR/Cas9-based genome editing
(Figures 7F, S5A, and S5B). CRISPR/Cas9-mediated GPC6
knockout led to even more prominent neurite outgrowth than
was observed with shRNA (Figure 7F). Neurites induced upon
GPC6 silencing were fully resistant to LPA-induced contraction
(results not shown). In addition, GPC6 depletion resulted in
enhanced cell-matrix adhesion and reduced cell motility (Figures
7G and 7H). It thus appears that loss of GPC6 function is pheno-
typically equivalent to GDE2 overexpression. We also examined
a possible contributing role of GPC3 in regulating neurite
outgrowth using cells (IMR-32) that express both GPC3 and
GPC6 (Figures S4E and S4F), but found no effect of GPC3 deple-
tion on neurite formation (Figures S5C and S5D).
Finally, low GPC6 expression correlated significantly with
favorable outcome in neuroblastoma patients (Figure 8A);
no significant correlation was found for GPC3 (Figure S6).
When GDPD5 and GPC6 expressions were combined, patients
classified as GDPD5high/GPC6low showed the best disease
outcome, whereas the GDPD5low/GPC6high group had the poor-
est outcome (Figure 8B). This result is consistent with the func-
tional interaction between GDE2 and GPC6 observed in neuro-
blastoma cell culture.556 Cancer Cell 30, 548–562, October 10, 2016DISCUSSION
In this study, we have identified and char-
acterized transmembrane ecto-phospho-
diesterase GDE2 as an inducer of neuro-
blastoma differentiation and as a powerful
prognosticmarker.We find that GDE2, pre-
viously shown to promote neurogenesis(Rao and Sockanathan, 2005), acts through an enzymatic mech-
anism involving cleavage of the GPI-anchor of GPC6. In the
simplest model compatible with our findings, GDE2 releases
GPC6 from the cell surface to modulate the activity of an as
yet unknown transmembrane effector (Figure 8C), which leads
to Rac activation, suppression of RhoA activity, and altered
gene expression. Together, these events direct neuroblastoma
differentiation as evidenced by neurite outgrowth, increased
cell-matrix adhesion, reduced cell motility, and blockade of
agonist-induced neurite retraction. The set of GDE2-regulated
genes was markedly enriched in those involved in neuronal dif-
ferentiation, cell-matrix adhesion, and transmembrane receptor
signaling. Future studies should assess whether a subset of
these genes contributes to the GDE2-induced phenotypes
and/or may represent a gene signature predictive of clinical
outcome.
Although GDE2 can also release GPC3, and GPC3 has been
implicated in the progression of various types of cancer (Filmus
and Capurro, 2013; Han et al., 2016; Peters et al., 2003), we find
that (1) GPC3 is not expressed two of our model neuroblastoma
cell lines (SH-SY5Yand N1E-115), (2) GPC3 knockdown does
not affect neurite outgrowth in IMR-32 cells, and (3) GPC3
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B Figure 6. Mutating His233 Abolishes GDE2
Biological Activity
(A) N1E-115 cells were transfected with wild-
type GDE2, GDE2(H233A), GDE2(H275A), or
GDE2(C25S) (mCherry-tagged), as indicated. At
24 hr after transfection, cells were stained with
phalloidin to visualize F-actin. GDE2 is shown in
red and F-actin in green. Scale bars, 10 mm.
(B) N1E-115 cells were transfected with wild-type
GDE2 or the indicated mutants (mCherry-tagged).
At 24 hr after transfection, GDE2 expression was
analyzed by immunoblotting using GDE2 anti-
body. b-Actin was used as loading control.
(C) Quantification of the morphological changes
shown in (A). (Left) Percentage of N1E-115 cells
with a round or flattened morphology. (Right)
Neurite length quantification. Cells were trans-
fected with pcDNA3 empty vector combined with
mCherry as control (three independent experi-
ments with >300 cells per experiment). Error bars
denote mean ± SEM. ***p < 0.001, ****p < 0.0001,
unpaired t test.expression levels, unlike those of GPC6, do not correlate with
clinical outcome. Nevertheless, it will be interesting to explore
whether and howGDE2-mediated release of GPC3may regulate
signaling pathways and cellular phenotypes in other types of
cancer or during development.
The cell-autonomous GDE2-GPC6 signaling axis underlying
neuroblastoma differentiation contrasts with the non-cell-auton-
omous GDE2-RECK-Notch pathway that promotes neurogene-
sis in the spinal cord (Park et al., 2013; Sabharwal et al., 2011).
Our efforts to detect RECK release (Park et al., 2013) by human
GDE2 were unsuccessful, suggestive of differential substrate
preferences among vertebrate GDE2 enzymes. Moreover,
GDE2 was unable to release GPCs 1, 2, 4, and 5, indicating
that GDE2 is highly selective toward GPI-anchored substrates
under our experimental conditions. Some caution is needed,
however, since the GDE2 activity assays were conducted in
HEK293 cells, and the availability of GPI-anchored substrates
may depend on local membrane lipid organization and structure
(Raghupathy et al., 2015). In addition, GDE2 substrate selectivity
may be dictated by structural modifications in the oligosaccha-
ride core of the respective GPI anchors and/or, in the case of
GPCs, by the nature of the heparan sulfate chains located close
to the cell surface (Veugelers et al., 1999), and hence may phys-
ically interact with the GDE2 ectodomain. We identified His233
as key catalytic residue of GDE2, but as yet it remains unclear
whether GDE2 acts as a PLC- or PLD-type phosphodiesteraseCanc(Park et al., 2013). Regardless of how
GDE2 selects and hydrolyzes its GPI-
anchored substrates, the evidence from
the present and previous studies (Park
et al., 2013) suggests that GDE2
may signal in both cell-autonomous and
non-cell-autonomous modes to induce
neuronal differentiation, depending on
cell and tissue context.
Our findings raise a number of new
questions. Foremost, how does GDE2-induced cleavage of GPC6 at the cell surface activate down-
stream signaling events? In other words, what is the GPC6-regu-
lated transmembrane effector? Despite many advances in
heparan sulfate proteoglycan research, our understanding of
GPC outside-in signaling is still very limited, and that of GPC6
in particular. In fact, GPC6 is the least studied and arguably
the most enigmatic GPC family member. Where studied, GPCs
can function as co-receptors to regulate transmembrane
signaling in various ways, both positively and negatively (Filmus
and Capurro, 2014; Filmus et al., 2008). As such, certain GPCs
can bind specific ligands, includingWnt and Hedgehog proteins,
and present them to cognate receptors. However, the emerging
picture of GPC-regulated Wnt signaling is complex, involving
both canonical and non-canonical signaling cascades, and to
date has not led to a unifying model; moreover, findings are
sometimes contradictory (Capurro et al., 2005, 2014; Yiu et al.,
2011). Whatever the possible role of GPC6 in Wnt signaling,
the finding that GDE2 acts cell autonomously, not requiring
nearby cells or extrinsic factors, seems difficult to reconcile
with a role for secreted Wnt ligands in GDE2-induced neuronal
differentiation; however, we cannot formally rule out a possible
cooperation with secreted ligands such as Wnt.
Interestingly, emerging evidence suggests that GPCs can also
function as ligands themselves by binding to transmembrane re-
ceptors, namely type II receptor protein tyrosine phosphatases
(RPTPs) (Coles et al., 2011, 2015). Type II RPTPs influenceer Cell 30, 548–562, October 10, 2016 557
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Figure 7. GPC6 Silencing Phenocopies GDE2 Overexpression and Correlates with Favorable Outcome
(A) Glypican mRNA expression (relative to GAPDH) in SH-SY5Y cells (qPCR analysis). Error bars denote mean ± SEM (triplicate measurements).
(B) (Left) Cell-surface expression of GDE2-mCherry before (black) and after (red) doxycyclin (Dox) treatment of SH-SY5Y cells, as detected by flow cytometry.
(Right) Cell-surface expression of GPC6 inGDE2-negative (black) andGDE2-positive (red) SH-SY5Y cells, as detected by flow cytometry. Control or Dox-induced
(legend continued on next page)
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Figure 8. Prognostic Significance of GPC6
and Signaling Scheme of GDE2
(A) Kaplan-Meier analysis of overall survival in a set
of 498 neuroblastoma patients (RPM cohort). Pa-
tients were classified using the same GPC6 cutoff
value. See also Figure S6.
(B) Kaplan-Meier analysis based on the combined
expression status of GDPD5 and GPC6 (AMC
patient cohort).
(C) Proposed GDE2 signaling scheme. In this
model, GDE2 acts through GPI-anchor cleavage
of GPC6, leading to GPC6 release from the cell
surface with consequent loss of interaction with an
as yet unknown transmembrane effector or re-
ceptor. This leads to Rac1 activation, increased
cell adhesion and spreading, neurite outgrowth,
reduced cell motility, and inhibition of LPA-G12/13-
RhoA-driven neurite retraction. Additionally GDE2
regulates a unique set of genes involved in
neuronal differentiation, cytoskeletal organization,
and cell-matrix adhesion (Figure 4I and Table S1).
GDE2 cell-surface expression may be regulated
by a Rab11-driven endocytic recycling pathway
(Figures S1G and S1H), as illustrated. See text for
further details.neuronal morphology and havemultiple intracellular binding part-
ners, including regulators of Rac/Rho activity (Chagnon et al.,
2010; Coles et al., 2015). Heparan sulfate proteoglycans can
directly interact (in cis) with the ectodomain of RPTPs tomodulate
RPTP oligomerization and transmembrane signaling (Coles et al.,
2011, 2015). Loss of aGPC ligandmight then lead to alteredRPTP
clustering at the plasma membrane with a consequent change in
localized levels of tyrosine phosphorylated proteins involved inGDE2 cells were labeled with second antibody alone (second Ab) or anti-GPC6 antibody. Bar graph shows q
experiments. *p < 0.05, paired t test.
(C) GPC6 knockdown in SH-SY5Y cells as determined by qPCR. GPC6 mRNA levels were normalized to GA
(D) Western blot showing that GPC6 depletion increases basal and LPA-stimulated Rac activity (SH-SY5Y ce
GTP levels in the presence or absence of LPA (mean ± SEM of three independent experiments). *p < 0.05, u
(E) GPC6 depletion leads to longer neurites (arrowheads) in SH-SY5Y cells. Scale bars, 100 mm. Bar graph sho
GPC6 knockdown cells (n = 250, mean ± SEM). ****p < 0.001, unpaired t test.
(F) CRISPR/Cas9-mediated GPC6 knockout promotes neurite outgrowth in SH-SY5Y cells (black arrows). S
neurite-bearing cells in CRISPR-GPC6 knockout cells (nR 500 cells, n = 11 colonies, mean ± SEM). ****p <
(G) shControl and shGPC6 were plated on fibronectin or laminin. At 1 hr after plating, adherent cells were fix
Error bars denote mean ± SEM of two independent experiments. *p < 0.05, unpaired t test.
(H) Quantification of average distances of cell migration of shControl and shGPC6 SY5Y cells. Error bars
***p < 0.001, unpaired t test.
See also Figure S5.
Cancsignaling pathways that stimulate neurite
outgrowth. Precisely how GPCs in gen-
eral, and GPC6 in particular, may affect
RPTP clustering and activity, and whether
RPTPs can act as a signaling intermediate
in GDE2 action awaits further studies.
Another outstanding question con-
cerns the regulation of GDE2 activity.
We could not confirm the proposed role
of cytosolic disulfide bonding in regu-
lating GDE2 activity (Novitch and Butler,
2009; Yan et al., 2009). A relatively large
proportion of GDE2 was detected inRab11- and TrfR-positive recycling endosomes, supporting a
model in which GDE2 activity is regulated at the level of cell-sur-
face expression by membrane trafficking (Figure 8C). Interest-
ingly, a recent study supports a scenario in which GDE2 is regu-
lated by intracellular trafficking (Yan et al., 2015). Regulation of
GDE2 activity by C-terminal tail phosphorylation is another plau-
sible scenario that warrants further investigation (Topanurak
et al., 2013).uantification (mean ± SEM) from three independent
PDH. **p < 0.01, ****p < 0.001, unpaired t test.
lls). Bar graph shows quantification of relative Rac-
npaired t test.
ws quantification of neurite length in control versus
cale bars, 100 mm. Bar graph shows percentage of
0.0001.
ed and stained with crystal violet for quantification.
denote mean ± SEM (>60 cells). ****p < 0.0001,
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The identification of GDE2 as an inducer of neuroblastoma cell
differentiation and as a favorable prognostic marker is consistent
with the finding that patient survival is largely dependent on the
degree of neuronal differentiation (Louis and Shohet, 2015).
New therapeutic approaches are urgently needed in neuroblas-
toma, but their development has been hampered by the paucity
of tractable oncogenic drivers (Molenaar et al., 2012; Pugh et al.,
2013) and an incomplete understanding of neuroblastoma differ-
entiation. In this respect, the present results open up possibilities
for exploring new therapeutic approaches. In particular, pharma-
cological stimulation of GDE2 activity could be a promising
strategy, not least because exo-/ecto-phosphodiesterases are
convenient drug targets. Therefore, the development of drug-
like allosteric activators of GDE2 could be valuable for targeted
differentiation therapy in neuroblastoma. Further structural and
preclinical studies will be needed to confirm the feasibility and
efficacy of this approach.
EXPERIMENTAL PROCEDURES
Human Datasets and Survival Analysis
All mRNA gene expression analyses were performed within R2: genomics
analysis and visualization platform (http://r2.amc.nl). We have made use of
the following publicly available datasets: Neuroblastoma Oberthuer (ArrayEx-
press: E-TABM-38), Neuroblastoma SEQC (GEO: GSE62564), and Neuroblas-
toma Versteeg (GEO: GSE16476 88/122). Kaplan scanning was performed
within R2 (http://r2.amc.nl). In brief, for each gene or other numerical charac-
teristic R2 calculates the optimal cutoff expression level, dividing the patients
in a good and bad prognosis cohort. Samples within a dataset are sorted ac-
cording to the expression of the investigated gene and divided into two groups
on the basis of a cutoff expression value. All cutoff expression levels and their
resulting groups are analyzed for survival, with the provision that minimal
group number is eight (or any other user-defined value) samples. For each cut-
off level and grouping, the log-rank significance of the projected survival is
calculated as described by Bewick et al. (2004). The best p value and corre-
sponding cutoff value is selected. This cutoff level is reported and used to
generate Kaplan-Meier graphs.
Materials, Cell Culture, Antibodies, and Expression Vectors
Reagents, cell culture, expression vectors, and transfection protocols are
described in Supplemental Experimental Procedures. A GDE2 polyclonal anti-
body was raised against the very C-terminal tail of human GDE2 (sequence
MVRHQPLQYYEPQ) and affinity purified, as described in Supplemental
Experimental Procedures.
Cell Morphology and Neurite Induction
Phenotypic analyses were done as described in Supplemental Experimental
Procedures.
Gene Silencing
shRNA-mediated knockdown and CRISPR/Cas9-mediated knockout experi-
mentswere performed as described in Supplemental Experimental Procedures.
Differential Gene Expression by RNA-Seq
Differential gene expression in GDE2 knockdown versus control Shep2 cells
was analyzed by whole-genome RNA-seq as described in Supplemental
Experimental Procedures.
qRT-PCR and Western Blotting
Real-time qPCR and western blotting assays were carried out as described in
Supplemental Experimental Procedures.
Microscopy and Live Imaging
Confocal and super-resolution microscopy assays and live imaging protocols
are described in Supplemental Experimental Procedures.560 Cancer Cell 30, 548–562, October 10, 2016Cell Adhesion and Motility Assays
Cell adhesion and random cell motility were measured as detailed in Supple-
mental Experimental Procedures.
GDE2 Enzymatic Activity Assays
GDE2 activity assays were carried out in HEK293 cells, essentially as
described by Park et al. (2013). HEK293 cells were seeded on polyethylenei-
mine-coated 6-well plates and co-transfected with expression vectors for
chicken or human GDE2 together with substrates (RECK-Myc, GPC(1–6)-
HA). GDE2 mutations were made using X-tremeGene 9 reagent (Roche). At
24 hr after transfection, cells were incubated for an additional 24 hr in
serum-free DMEM. The conditioned medium was removed and cell lysates
were prepared using NP-40/NaDOC lysis buffer (50 mM Tris [pH 7.4],
150 mMNaCl, 2 mM EDTA, 1%NP-40, 0.25% NaDOC, and 5% glycerol) sup-
plemented with protease inhibitor cocktail. The amount of substrate proteins in
the medium and cell lysates was analyzed by western blotting.
Rac and RhoA Activity Assays
Activities of Rac and RhoA were measured by pull-down assays as described
in Supplemental Experimental Procedures.
RhoA Activation Measurements
To monitor RhoA activity in real time, we transfected cells with an RhoA-spe-
cific FRET-based biosensor in which the HR1 region of protein kinase N was
used as the effector domain for activated RhoA, essentially as described by
Kedziora et al. (2016). Further details and RhoA activity monitoring in single
cells are described in Supplemental Experimental Procedures.
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